A Safety Study of Brentuximab Vedotin in Participants With HIV
Key facts
- Who runs it
- Seagen Inc.
- Where
- Chicago and San Francisco, United StatesSee the 2 sites
- Trial code
- Status
- Withdrawn
- Phase
- Phase 1
- Started
- 31 Dec 2022
- Ended
- 31 May 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- brentuximab vedotin
- Placebo
- ART
- Record updated
- 14 February 2023
- Why it stopped
- Study withdrawn due to low patient accrual.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- HIV-1 seropositive with documentation of infection
- Immunological nonresponder, defined as:; Has been on ART with an HIV viral load <50 copies/mL for at least 24 months; Has a CD4+ T-cell lymphocyte count between 51 to 200 cells/µL
- Life expectancy of >9 months
- Participant is negative for hepatitis B, or if infected with hepatitis B, receiving anti-hepatitis B therapy
- Participants with a history of hepatitis C virus (HCV) are eligible if they have completed therapy for HCV and show sustained virologic remission (12 weeks or more)
Who cannot take part
- Prior clinical John Cunningham virus (JCV) infection, history of JCV identified in cerebrospinal fluid, or presence of JCV antibodies at screening
- Any immunomodulating therapy (excluding premedication steroid) within 4 weeks prior to the screening visit
- Any currently active AIDS-defining illness per Category C conditions according to the CDC Classification System for HIV Infection, with the following exceptions:; Limited cutaneous Kaposi's sarcoma not currently requiring systemic therapy; Wasting syndrome due to HIV or any other AIDS-defining illness for which no therapeutic treatment is required OR the required treatment is not included in the list of prohibited medications
- Acute liver disease or any other active infection secondary to HIV requiring acute therapy
- History of progressive multifocal leukoencephalopathy (PML)
- Prior malignancy within 2 years other than cutaneous basal cell or squamous cell carcinoma, carcinoma in situ of the cervix, anal intraepithelial neoplasia, or cutaneous Kaposi's sarcoma
- Cirrhosis secondary to any cause
Where in United States
- University of Illinois at ChicagoChicago, United States
- University of California at San FranciscoSan Francisco, United States
About the trial
What the trial wants to find out
This study will test brentuximab vedotin to see if it is safe for people with human immunodeficiency virus (HIV) who have low CD4+ and have received antiretroviral therapy (ART) treatment. It will also see if brentuximab vedotin raises CD4+ counts. It will study the side effects of this drug as well. A side effect is anything a drug does to the body besides treating the disease.
Read full original descriptionShow less
In this study participants will be assigned randomly to a group. Participants will get either brentuximab vedotin or placebo. A placebo looks like the drug but does not contain any medicine in it. All participants will keep getting ART during the study.
The 2 groups in the trial
- Brentuximab vedotin + ARTTreatment being tested
Brentuximab vedotin given on Day 1 and Day 15. ART will be given throughout the study.
Treatment: brentuximab vedotin and ART
- Placebo + ARTPlacebo, for comparison
Placebo given on Day 1 and Day 15. ART will be given throughout the study.
Treatment: Placebo and ART
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1, Single-blind, Dose-escalation Study to Assess the Safety and Tolerability of Brentuximab Vedotin (ADCETRIS®) in Subjects With Human Immunodeficiency Virus (HIV)
- Record updated
- 14 February 2023